{"id":"lcz-696","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LCZ696 combines valsartan (an ARB) with sacubitril (a neprilysin inhibitor) in a single molecule. By blocking AT1 receptors, it reduces vasoconstriction and aldosterone secretion; simultaneously, neprilysin inhibition prevents degradation of natriuretic peptides, enhancing their beneficial vasodilatory and diuretic effects. This dual mechanism provides superior hemodynamic and neurohormonal benefits compared to ACE inhibitors or ARBs alone.","oneSentence":"LCZ696 is a dual angiotensin receptor-neprilysin inhibitor (ARNI) that blocks angiotensin II signaling while inhibiting neprilysin to increase natriuretic peptides.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:44.772Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT05168787","phase":"","title":"Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2020-08-13","conditions":"Heart Failure","enrollment":6558},{"nctId":"NCT07491718","phase":"NA","title":"Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-08-08","conditions":"Takotsubo Cardiomyopathy","enrollment":100},{"nctId":"NCT07486453","phase":"PHASE1","title":"Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2026-03-09","conditions":"Primary Hypertension","enrollment":60},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT05194111","phase":"PHASE1, PHASE2","title":"Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2022-08-11","conditions":"Heart Failure, Heart Dysfunction","enrollment":53},{"nctId":"NCT07465679","phase":"","title":"A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-28","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":500},{"nctId":"NCT07465653","phase":"PHASE1","title":"A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-19","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":12},{"nctId":"NCT07465666","phase":"","title":"A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-01","conditions":"Hypertension","enrollment":500},{"nctId":"NCT04153136","phase":"PHASE2","title":"The ENCHANTMENT HIV Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-09-11","conditions":"HIV/AIDS, Heart Failure With Preserved Ejection Fraction","enrollment":39},{"nctId":"NCT07444398","phase":"PHASE1","title":"Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial","status":"RECRUITING","sponsor":"Khawaja Danish Ali","startDate":"2026-01-01","conditions":"Decompensated Heart Failure","enrollment":130},{"nctId":"NCT06536309","phase":"PHASE4","title":"Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-07","conditions":"Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis","enrollment":36},{"nctId":"NCT07417215","phase":"PHASE4","title":"The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF","status":"NOT_YET_RECRUITING","sponsor":"University Clinical Hospital Mostar","startDate":"2026-01-30","conditions":"Heart Failure With Preserved Ejection Fraction (HFPEF), Hemodialysis, Sacubitril/Valsartan","enrollment":60},{"nctId":"NCT05528419","phase":"PHASE4","title":"Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-02-06","conditions":"Atrial Fibrillation Recurrent, Hypertension","enrollment":320},{"nctId":"NCT07376265","phase":"","title":"A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-20","conditions":"Heart Failure","enrollment":1249},{"nctId":"NCT07379788","phase":"","title":"ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling","status":"RECRUITING","sponsor":"Rehab Werida","startDate":"2025-12-25","conditions":"Heart Failure","enrollment":180},{"nctId":"NCT03872778","phase":"PHASE1, PHASE2","title":"[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2019-05-24","conditions":"Neoplasms","enrollment":35},{"nctId":"NCT06142383","phase":"PHASE2","title":"A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-12","conditions":"Heart Failure","enrollment":136},{"nctId":"NCT07347925","phase":"","title":"Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF","status":"RECRUITING","sponsor":"Future University in Egypt","startDate":"2026-01-10","conditions":"Heart Failure","enrollment":140},{"nctId":"NCT07341893","phase":"NA","title":"Sacubitril-valsartan in Patients With Heart Failure.","status":"RECRUITING","sponsor":"Damanhour University","startDate":"2025-08-01","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT06237309","phase":"PHASE2","title":"REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-11","conditions":"Heart Failure","enrollment":89},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT06236061","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Hypertension","enrollment":718},{"nctId":"NCT06029712","phase":"PHASE2","title":"Heart Failure Polypill at a Safety Net Hospital","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-02-27","conditions":"Heart Failure With Reduced Ejection Fraction, HIV Infections","enrollment":35},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":"AMI, STEMI, NSTEMI","enrollment":450},{"nctId":"NCT05991284","phase":"PHASE4","title":"Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2024-02-29","conditions":"Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation","enrollment":84},{"nctId":"NCT03744975","phase":"PHASE2","title":"PDD in Type 2 Diabetes w/wo Diastolic Dysfunction","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-05-01","conditions":"Diabetes Mellitus, Type 2, Diastolic Dysfunction","enrollment":72},{"nctId":"NCT06643819","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-10-14","conditions":"Essential Hypertension","enrollment":324},{"nctId":"NCT05498181","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-10-11","conditions":"Hemodialysis","enrollment":100},{"nctId":"NCT07241338","phase":"PHASE4","title":"Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity","status":"NOT_YET_RECRUITING","sponsor":"Jing Liu","startDate":"2025-11","conditions":"Hypertension","enrollment":104},{"nctId":"NCT05989503","phase":"PHASE4","title":"Initiation of ARNi and SGLT2i in Patients With HFrEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2023-08-04","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":62},{"nctId":"NCT04023227","phase":"PHASE4","title":"Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-12-10","conditions":"Chagas Disease, Heart Failure","enrollment":918},{"nctId":"NCT07232966","phase":"PHASE3","title":"Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Yan Li","startDate":"2025-11-20","conditions":"Resistant Hypertension","enrollment":220},{"nctId":"NCT06149104","phase":"PHASE3","title":"A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-04","conditions":"Heart Failure","enrollment":8},{"nctId":"NCT05279742","phase":"PHASE1, PHASE2","title":"Enhancing the Natriuretic Peptide System in HFpEF","status":"ENROLLING_BY_INVITATION","sponsor":"Horng Chen","startDate":"2022-11-04","conditions":"Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT06693674","phase":"PHASE3","title":"Effect of Sacubitril-Valsartan on Cardiac Structure and Function","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-02-03","conditions":"Congenital Heart Disease","enrollment":45},{"nctId":"NCT07192341","phase":"NA","title":"Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2025-09-27","conditions":"Sacubitril/Valsartan, Prosthetic Heart Valve, Heart Failure","enrollment":220},{"nctId":"NCT07197372","phase":"","title":"Comparative Efficacy of ARNI Versus ACE Inhibitor Therapy in Egyptian Children With Dilated Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-30","conditions":"ARNI, Pediatric Dilated Cardiomyopathy, ACE Inhibitor","enrollment":70},{"nctId":"NCT06659393","phase":"","title":"Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-12-19","conditions":"Pediatric Chronic Heart Failure","enrollment":33},{"nctId":"NCT03508739","phase":"PHASE3","title":"Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition","status":"SUSPENDED","sponsor":"University of Pennsylvania","startDate":"2018-06-01","conditions":"Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension","enrollment":25},{"nctId":"NCT07157527","phase":"","title":"Impact of Sacubitril/Valsartan on LV Diastolic Function in HFrEF","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-06-01","conditions":"Left Ventricular Diastolic Function","enrollment":70},{"nctId":"NCT06704633","phase":"PHASE4","title":"Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania","status":"NOT_YET_RECRUITING","sponsor":"Martin Rohacek","startDate":"2026-01-05","conditions":"Heart Failure","enrollment":238},{"nctId":"NCT06917664","phase":"PHASE4","title":"Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-06-05","conditions":"Coronary Artery Disease, Ischemic Mitral Regurgitation, Angiotensin Receptor/Neprilysin Inhibitor","enrollment":220},{"nctId":"NCT04113109","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-01","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT05636774","phase":"NA","title":"Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2022-12-12","conditions":"Patients With Advanced Cancer Receiving Specialized Palliative Care","enrollment":97},{"nctId":"NCT07130175","phase":"NA","title":"Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)","status":"COMPLETED","sponsor":"Qian Feng","startDate":"2022-12-31","conditions":"Polymorphic Ventricular Tachycardia, Heart Failure","enrollment":118},{"nctId":"NCT03938389","phase":"PHASE4","title":"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2020-02-25","conditions":"PreDiabetes, Impaired Glucose Tolerance, Obesity","enrollment":90},{"nctId":"NCT07088471","phase":"","title":"Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Connolly Hospital Blanchardstown","startDate":"2024-11-01","conditions":"Heart Failure and Reduced Ejection Fraction","enrollment":334},{"nctId":"NCT03738878","phase":"PHASE4","title":"Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-11-15","conditions":"Hypertension","enrollment":4},{"nctId":"NCT04055428","phase":"PHASE2","title":"NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-15","conditions":"Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance","enrollment":200},{"nctId":"NCT05976230","phase":"","title":"Special Drug Use Surveillance of Entresto Tablets (Hypertension)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-09-04","conditions":"Hypertension","enrollment":1125},{"nctId":"NCT03553810","phase":"PHASE2","title":"Role of ARNi in Ventricular Remodeling in Hypertensive LVH","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-04-12","conditions":"Hypertensive Heart Disease","enrollment":80},{"nctId":"NCT07023016","phase":"PHASE2, PHASE3","title":"Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"National Heart Institute, Egypt","startDate":"2023-11-01","conditions":"Acute Decompensated Heart Failure (ADHF), Chronic Kidney Disease (CKD)","enrollment":515},{"nctId":"NCT05353166","phase":"PHASE2","title":"REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-06-30","conditions":"Heart Failure","enrollment":59},{"nctId":"NCT03928158","phase":"PHASE2","title":"LCZ696 in Advanced LV Hypertrophy and HFpEF","status":"COMPLETED","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2019-05-31","conditions":"Heart Failure, Essential Hypertension","enrollment":61},{"nctId":"NCT04491136","phase":"PHASE4","title":"Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-11","conditions":"Heart Failure","enrollment":201},{"nctId":"NCT03785405","phase":"PHASE3","title":"Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-02","conditions":"Heart Failure","enrollment":216},{"nctId":"NCT04164732","phase":"PHASE2","title":"Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-01-08","conditions":"Cardiomyopathy, Hypertrophic","enrollment":46},{"nctId":"NCT04971720","phase":"PHASE2, PHASE3","title":"PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-18","conditions":"Obesity, Cardiovascular Diseases, Hypertension","enrollment":160},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":60},{"nctId":"NCT06922253","phase":"PHASE1","title":"Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2024-12-28","conditions":"Chronic Heart Failure","enrollment":48},{"nctId":"NCT06900803","phase":"NA","title":"Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-07","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan, Medication Adherence","enrollment":200},{"nctId":"NCT05465031","phase":"PHASE4","title":"Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)","status":"RECRUITING","sponsor":"Silesian Centre for Heart Diseases","startDate":"2024-04-17","conditions":"Breast Cancer, Neoplasm, Breast, Breast Diseases","enrollment":600},{"nctId":"NCT05021419","phase":"NA","title":"Efficacy of a Streamlined Heart Failure Optimization Protocol","status":"COMPLETED","sponsor":"The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust","startDate":"2022-07-17","conditions":"Heart Failure with Reduced Ejection Fraction, Chronic Heart Failure","enrollment":60},{"nctId":"NCT03988634","phase":"PHASE3","title":"Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-29","conditions":"Heart Failure With Preserved Ejection Fraction (HFpEF)","enrollment":467},{"nctId":"NCT04637152","phase":"PHASE2","title":"Sacubitril/Valsartan in Resistant Hypertension","status":"COMPLETED","sponsor":"Hospital Geral Roberto Santos","startDate":"2020-11-11","conditions":"Resistant Hypertension, Blood Pressure","enrollment":80},{"nctId":"NCT06655480","phase":"PHASE2","title":"Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF","status":"NOT_YET_RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2025-03-18","conditions":"HFpEF, LVDD, Myocardial Fibrosis","enrollment":50},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT03760588","phase":"PHASE2","title":"Prevention of Cardiac Dysfunction During Breast Cancer Therapy","status":"COMPLETED","sponsor":"Torbjorn Omland","startDate":"2019-01-31","conditions":"Breast Cancer Female, Heart Failure","enrollment":138},{"nctId":"NCT04149990","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI","status":"TERMINATED","sponsor":"Jacob Moller","startDate":"2018-10-12","conditions":"Myocardial Infarction, Diastolic Dysfunction","enrollment":51},{"nctId":"NCT06716970","phase":"PHASE3","title":"QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-12-30","conditions":"Essential Hypertension","enrollment":810},{"nctId":"NCT06712030","phase":"PHASE3","title":"Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Puerta de Hierro University Hospital","startDate":"2025-01","conditions":"Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","enrollment":114},{"nctId":"NCT04872959","phase":"NA","title":"TRANSFORM Heart Failure with Reduced Ejection Fraction","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2021-10-22","conditions":"Heart Failure, Systolic","enrollment":""},{"nctId":"NCT05508035","phase":"PHASE3","title":"The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction","status":"RECRUITING","sponsor":"John Paul II Hospital, Krakow","startDate":"2023-07-13","conditions":"Heart Failure with Moderately Reduced Ejection Fraction","enrollment":666},{"nctId":"NCT06604897","phase":"","title":"Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis","startDate":"2023-01-31","conditions":"Essential Hypertension","enrollment":1405},{"nctId":"NCT04587947","phase":"NA","title":"Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study","status":"COMPLETED","sponsor":"St. Josefs-Hospital Wiesbaden GmbH","startDate":"2020-04-01","conditions":"Heart Failure Patients","enrollment":63},{"nctId":"NCT06090487","phase":"NA","title":"Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-02-01","conditions":"Heart Failure","enrollment":30},{"nctId":"NCT06283420","phase":"","title":"Metabolic Response to the Initiation of Heart Failure Therapy","status":"RECRUITING","sponsor":"Vojtech Melenovsky, MD, PhD","startDate":"2024-08-23","conditions":"Heart Failure","enrollment":120},{"nctId":"NCT05164653","phase":"PHASE4","title":"Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Saga University","startDate":"2021-12-27","conditions":"Heart Failure","enrollment":400},{"nctId":"NCT02884206","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-23","conditions":"Chronic Heart Failure (CHF)","enrollment":592},{"nctId":"NCT06501651","phase":"PHASE4","title":"Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Academy of Medical Sciences","startDate":"2024-08-01","conditions":"Essential Hypertension, Type 2 Diabetes, Nephropathy","enrollment":297},{"nctId":"NCT04883528","phase":"PHASE1, PHASE2","title":"Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-08-06","conditions":"Covid19","enrollment":42},{"nctId":"NCT04707261","phase":"PHASE4","title":"Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)","status":"RECRUITING","sponsor":"Xiangtan Central Hospital","startDate":"2021-08-06","conditions":"Anemia, Heart Failure","enrollment":1990},{"nctId":"NCT06439069","phase":"","title":"BMI-Driven Tolerability and Efficacy of Entresto in Heart Failure Patients","status":"RECRUITING","sponsor":"Lithuanian University of Health Sciences","startDate":"2023-08-10","conditions":"Heart Failure, Obesity","enrollment":340},{"nctId":"NCT06357104","phase":"PHASE4","title":"Detoxification From the Lipid Tract","status":"COMPLETED","sponsor":"Pachankis, Yang I., M.D.","startDate":"2024-02-26","conditions":"COVID-19 Vaccine Adverse Reaction","enrollment":1},{"nctId":"NCT04853758","phase":"PHASE3","title":"Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-05-06","conditions":"Chagas Cardiomyopathy","enrollment":200},{"nctId":"NCT04103554","phase":"PHASE4","title":"Sacubitril/Valsartan in Left Ventricular Assist Device Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Zagreb","startDate":"2021-02-05","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT05117736","phase":"NA","title":"ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure","status":"TERMINATED","sponsor":"Montreal Heart Institute","startDate":"2022-03-15","conditions":"Systemic Right Ventricle, Heart Failure","enrollment":15},{"nctId":"NCT03917459","phase":"PHASE3","title":"COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-04-16","conditions":"Heart Failure, Heart Failure, Systolic, Erectile Dysfunction","enrollment":27},{"nctId":"NCT06273254","phase":"PHASE1","title":"A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions","status":"UNKNOWN","sponsor":"Viatris Inc.","startDate":"2024-04","conditions":"Bioequivalence Study","enrollment":48},{"nctId":"NCT06266988","phase":"PHASE1","title":"A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions","status":"UNKNOWN","sponsor":"Viatris Inc.","startDate":"2024-03","conditions":"Chronic Heart Failure","enrollment":48},{"nctId":"NCT06248112","phase":"PHASE1","title":"Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-05-06","conditions":"Healthy Subjects","enrollment":40},{"nctId":"NCT04434170","phase":"","title":"Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure","status":"COMPLETED","sponsor":"Centro Cardiologico Monzino","startDate":"2018-10-15","conditions":"Heart Failure","enrollment":112},{"nctId":"NCT06218199","phase":"PHASE4","title":"Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts","status":"RECRUITING","sponsor":"Heart Center Research, LLC","startDate":"2021-07-08","conditions":"Heart Failure, Congestive","enrollment":80},{"nctId":"NCT06035978","phase":"PHASE4","title":"Determination of Drug Levels for Pharmacotherapy of Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2024-03","conditions":"Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction","enrollment":100},{"nctId":"NCT03300427","phase":"PHASE4","title":"The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-05","conditions":"Heart Failure","enrollment":55},{"nctId":"NCT06193187","phase":"PHASE1","title":"A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions","status":"UNKNOWN","sponsor":"Dr. Reddy's Laboratories (Thailand) Limited","startDate":"2024-01","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT02468232","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-15","conditions":"Heart Failure With Reduced Ejection Fraction (HF-rEF)","enrollment":225},{"nctId":"NCT06149806","phase":"","title":"National Registry of Adult Heart Failure Patients With Complex Congenital Heart Disease: Systemic Right Ventricle and Single Ventricle Treated With Sacubitril/Valsartan","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2021-07-01","conditions":"Complex Congenital Heart Disease","enrollment":50},{"nctId":"NCT04736433","phase":"","title":"Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-22","conditions":"Heart Failure","enrollment":6066}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Entresto®)","ARNI","Entresto","sacubitril/valsartan"],"phase":"marketed","status":"active","brandName":"LCZ 696","genericName":"LCZ 696","companyName":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","companyId":"national-medical-research-center-for-cardiology-ministry-of-health-of-russian-fe","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LCZ696 is a dual angiotensin receptor-neprilysin inhibitor (ARNI) that blocks angiotensin II signaling while inhibiting neprilysin to increase natriuretic peptides. Used for Heart failure with reduced ejection fraction, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":9,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}